Navigation Links
Gluteal Implants

ProductsGluteal Implants
Company Hanson Medical, Inc.
Item Gluteal Implants
Features Inquire
Description Dimensions are accurate to 1 mm. In vivo results may be affected by the thickness of the patients encapsulation scar tissue. Encapsulation scar tissue can impact the desired augment-ation 1 to 2 mm; therefore actual projection may vary from patient to patient. Implant dimensions can be altered by the surgeon with a scalpel or surgical scissors. All dimensions in centimeters. This device is available by or on the order of a licensed physician only.
Info Hanson Medical, Inc.
Customer Service: (800) 771-2215
Web site: http://www.hansonmedical.com/index.html

Related medicine products :

1. Gluteal Implant
2. Cylindrical Sponge Implants - 3.0 x 80 mm
3. Olk Design Sponge Implants - 5.0 x 2.5 x 80 mm
4. Olk Design Sponge Implants - 7.5 x 2.75 x 80 mm
5. Cylindrical Sponge Implants - 4.0 x 80 mm
6. Cylindrical Sponge Implants - 5.0 x 80 mm
7. Oval Sponge Implants - 5.5 x 7.5 x 80 mm
8. Oval Sponge Implants - 3.0 x 5.0 x 100 mm
9. Contour Design Eyelid Implants
10. ThinProfile Design Eyelid Implants
11. Ocu-pore Porous Orbital Implants
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products:
(Date:10/10/2008).../ -- NuView Life Sciences Inc.,(NuView) has agreed...(Trace), including operations of the linear accele...n, Texas. The Trace facility produces,Copper-64, C... used in,molecular imaging and nuclear medicine. P...e are confident that by improving operational,effi...
(Date:10/10/2008)...blame , , FRIDAY, Oct. 10 (HealthDay New...e diabetes, being depressed was associated with a ... Publishing in the October issue of the Journal ...e University of Washington tracked 10,704 Medicare... diabetes and were enrolled in a disease managemen...
(Date:10/10/2008)...ientists have identified a protein that plays matc... T and B cells, enabling them to interact in a way...nity after an infection. Their finding may also e...ect that prevents them from making this proteincal... virus that otherwise is rarely fatal (Epstein-Bar...
(Date:10/10/2008)...- The Mobile Massage Team, (http://www.mobilemassa... massage,services for corporate wellness programs,...d today that it is expanding its service area thro...elphia metropolitan region., "We are quite excite...ted, massage programs and services throughout bot...
Breaking Medicine News(10 mins):Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:NIH scientists discover crucial control in long-lasting immunity 2Health News:NIH scientists discover crucial control in long-lasting immunity 3Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2
...a and television that anger causes// the cardiac a... dramatizations. Yale University researchers have ...r anxiety, may cause the muscles in the heart to t...h previous history of cardiac problems, although s...
...ce, UK, has provided new guidelines //for dealing ...w guidelines suggest that psychological therapy be...atural or man made is always tough. NICE had empha...clothing shelter to these traumatized people it is...
...rker that will help in medical practitioners to di... effective treatment.// Lupus is a condition that ...e body’s own immune system. Patients affected with...s in their blood that may attack the body’s own ti...
...habit of 6654 people for a period of eight years, ...g do causes weight gain, but the overall health ef...nder study was measured for effect of giving up on...ry lung function in 1991-93 when the age group was...
Other Medicine News:
(Date:10/8/2008)...RNewswire/ -- Vical Incorporated (Nasdaq: VICL ),... nonclinical data,demonstrating that the company,s...n DNA- and protein-based infectious disease vaccin...land, Pharm.D., Ph.D., Vical,s,Senior Vice Preside...oday,Wednesday, October 8, at the World Vaccine C...
(Date:10/7/2008)...- The Texas Cardiac Arrhythmia,Instit...selected as one of,only a few sites in the nation ...or a new device to treat persistent atrial fibrill...and research center specializing in heart,rhythm d...ical Center and,Texas Cardiovascular Consultants.,...
(Date:10/7/2008)...adults, VYVANSE taken once-daily significantly,imp...DELPHIA, Oct. 7 /- Shire pl...biopharmaceutical company, today,announced that a ...nal of,Clinical Psychiatry found once-daily VYVANS...tivity Disorder (ADHD) symptoms in adults within,t...
(Date:10/7/2008)...ighting CIMZIA,s long-term benefits and value in,m...ed at American College,of Gastroenterology (ACG), ...ta from two studies,presented this week by UCB at ...ual Meeting demonstrate that CIMZIA(R) (certolizum...or Necrosis Factor alpha) - provides,sustained imp...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 1Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 2Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 3Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 4Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 5BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 1BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 2BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 3Homeowners Admit to Dust Bunny Dilemma 570 1Homeowners Admit to Dust Bunny Dilemma 570 2Homeowners Admit to Dust Bunny Dilemma 570 3Homeowners Admit to Dust Bunny Dilemma 570 4Homeowners Admit to Dust Bunny Dilemma 570 5First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 1First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 2First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 3First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 4
...Demonstrates 50% Survival in Valortim-Treated Anim...9, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc. , ...hene, Inc., a privately held,biotechnology company...rmeasures, today announced that Valortim(TM), a fu...ing developed for the,prevention and treatment of ...
...SINESS WIRE)--Mar 29, 2007 - Cytogen,Corporation (...tion,of preclinical data at the 2007 Annual Meetin...(AACR) taking place in Los Angeles,California Apr...eclinical studies that validate novel approaches t...ompany,s proprietary,Abtides(TM) (Antigen-Binding ...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4